Hadassah performs first-ever alpha radiation treatment for recurring brain tumors
The technology, which emits highly bioefficient alpha particles that deliver concentrated radiation, was developed in collaboration with the Sharett Institute of Oncology and ALPHA Tau.
At Hadassah Medical Center in Jerusalem, a groundbreaking alpha radiation treatment for recurring brain tumors has been successfully performed for the very first time in the world. The innovative Alpha DaRT technology, developed in collaboration with the Sharett Institute of Oncology and ALPHA Tau, utilizes highly bioefficient alpha particles to target tumors with minimal damage to surrounding brain tissue.
The 77-year-old patient, diagnosed with a glioblastoma recurrence after previous treatments, became Israel's inaugural recipient of the Alpha DaRT therapy. This pioneering procedure involved injecting radiation sources from two pathways simultaneously, enabling optimal tumor coverage while maintaining exceptional accuracy.
Professor Yigal Shoshan, Director of Neurosurgery, Oncology, and Stereotactic Radiosurgery Unit at Hadassah, led the surgery alongside a multidisciplinary team from various departments. The results have garnered interest in the neuro-oncology community, as preliminary findings were published in the US. The technology's seamless integration with existing neurosurgical navigation systems further enhances its appeal.
Hadassah's Director of the Sharett Institute of Oncology, Professor Aron Popovtzer, emphasized the significance of glioblastoma being the most common primary malignant brain tumor in adults, with almost all patients experiencing recurrence despite standard treatments. The limited treatment options for recurrent disease underscore the importance of innovative therapies like Alpha DaRT.
Alpha Tau CEO Uzi Sofer hailed the treatment as a significant milestone for the company, emphasizing that the technology born in Israel will benefit Israeli patients. The study aims to examine the feasibility and safety of the treatment, with future plans to expand the clinical program to encompass targeted brain metastases.
Written by urgent.news from Jerusalem Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
